25b-NBOMe
25B-NBOMe is a synthetic psychedelic of the substituted phenethylamine class and a member of the 25x-NBOMe series. It is an N-benzyl derivative of 2C-B, first described by Ralf Heim at the Free University of Berlin. The substance had virtually no history of human use before appearing on the research chemical market in 2010. Compared to its parent compound 2C-B, 25B-NBOMe is reported to be approximately sixteen times more potent.
Contents
Dosage & Duration
Dosage
Hold blotter sublingually for 15-30 minutes to ensure proper absorption. The compound exhibits minimal oral bioavailability and must not be swallowed immediately. Fatalities have been documented at heavy doses.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of 25B-NBOMe can be broken down into six components all of which progressively intensify proportional to dosage.
Cognitive
The head space of 25B-NBOMe is described by many as remarkably light and underwhelming in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages however, mild to overwhelming cognitive alterations become present.
Visual
Geometry
The visual geometry that is present throughout this trip is often described as similar in appearance to that of LSD. They can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colourful in scheme, glossy in colour, sharp around the edges and mostly rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages. In terms of their behaviour, 25B-NBOMe's geometry leads onto Level 7A visual geometry with Level 7B remaining so far unconfirmed within this substance. They also seem to consistently build up in visual intensity when the tripper stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
Hallucinatory States
25B-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very uncommon and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.
Auditory
The auditory effects of 25B-NBOMe are common in their occurrence and exhibit a full range of effects.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
25B-NBOMe is a selective serotonin 5-HT2 receptor agonist that acts as a potent partial agonist at the 5-HT2A receptor. It binds with high affinity to 5-HT2A, 5-HT2B, and 5-HT2C receptors, though the degree of subtype selectivity varies between studies: one reported similar affinity across all three subtypes (Ki = 0.5–1.7 nM), while another found 12- to 20-fold selectivity for 5-HT2A (Ki = 0.5 nM) over 5-HT2B and 5-HT2C (Ki = 10 and 6.2 nM, respectively). The compound is highly selective for 5-HT2 receptors over other serotonin receptors, monoamine receptors, and monoamine transporters (>200-fold). In rodent models, 25B-NBOMe increases cortical and subcortical levels of glutamate, serotonin, dopamine, and acetylcholine, with these elevations following an inverted U-shaped dose-response curve. It also acts as a low-potency partial agonist at rat and mouse TAAR1, though it is inactive at the human form of this receptor.
Pharmacokinetics
Tolerance
Psychedelics (all serotonergic psychedelics will have reduced effect following 25B-NBOMe consumption)
Harm Potential
Addiction & Dependence
Psychological
Low25B-NBOMe has demonstrated reinforcing effects in rodent studies, producing conditioned place preference and self-administration with robust dopamine elevation in the nucleus accumbens. However, the rapid tolerance development that occurs immediately after ingestion makes compulsive use essentially impossible, and the substance is generally considered not habit-forming with desire to use often decreasing after experiences.
Toxicity
Vasoconstriction, tachycardia, and elevated blood pressure commonly occur during intoxication; in overdose situations these effects intensify significantly and may potentially result in organ failure or cardiac arrest.
Psychosis Risk
Overdose effects commonly include confusion, delusions, panic attacks, and aggressive behavior. These psychotomimetic effects appear dose-dependent and are more likely at higher doses.
Seizure Risk
NBOMes have shown a tendency to cause severe seizures, which are commonly reported among overdose symptoms. The substance appears to lower seizure threshold.
History & Culture
25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin, with initial findings presented in conference abstracts as early as 1999. The compound was subsequently characterized in more detail through continued research at the institution…
Legality
By Country
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25b-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.